Current pathophysiological aspects of systemic sclerosis;Aktuelle pathophysiologische aspekte der systemischen sklerose

Zeitschrift fur Rheumatologie

Volumn 65, Issue 4, 2006, Pages 275-278

  Krieg, T ^a   Hunzelmann, N ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Connective tissue; Endothelial cell; Fibroblast; Fibrosis; Hypoxia

Indexed keywords

PROTEIN;

ATROPHY; CONNECTIVE TISSUE; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW; SKIN ATROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CELL HYPOXIA; COLLAGEN; CONNECTIVE TISSUE; DISEASE MODELS, ANIMAL; ENDOSTATINS; ENDOTHELIAL CELLS; ENDOTHELIN-1; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MICE; SCLERODERMA, SYSTEMIC; VASOCONSTRICTION;

EID: 33746392795     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0066-z     Document Type: Review

References (26)

1. Arbuckle MR, Mcclain MT, Rubertone MV et al. (2003) Development of autoantibodies before the clinical onset of lupus erythematosus. New Engl J Med 349: 1526-1533
2. Arlett C, Smith BR, Jimenez SA (1998) New perspectives on the etiology of systemic sclerosis. New Engl J Med 338: 1186-1189
3. Brinckmann J, Kim S, Wu J et al. (2005) Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol 24: 459-468
4. Chujo S, Shirasaki F, Kawara S et al. (2005) Connective tissue growth factor causes persistent proalpha2(1) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 203: 447-456
5. Davies CA, Jeziorska M, Freemont AJ, Herrick AL (2005) The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37: 190-197
6. Denton CP, Abraham DJ (2001) Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13: 505-511
7. Denton CP, Abraham DJ (2004) Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun Rev 3: 285-293
8. Distler O, Del Rosso A, Giacomelli R et al. (2002) Angiogenic and gniostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4: R11
9. Dziadzio M, Smith RE, Abraham DJ et al. (2004) Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 22: 356-367
10. Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5: 80-93
11. Horstmeyer A, Licht C, Scherr G et al. (2005) Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta 1. FEBS J 272: 6297-6309
12. Hunzelmann N, Risteli J, Risteli L et al. (1998) Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? Br J Dermatol 139: 1020-1025
13. Igarashi A, Nashiro K, Kikuchi K et al. (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105: 280-284
14. Kawakami T, Ihn H, Xu W et al. (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110: 47-51
15. Kim WU, Min SY, Cho ML et al. (2005) Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 7: R71-R79
16. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T (1990) Co-localization of transforming growth factor β2 with a1(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86: 917-921
17. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2005) Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24: 111-116
18. Kuwana M, Okazaki Y, Yasuoka H et al. (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364: 603-610
19. Mayes MD (2003) Scleroderma epidemiology. Rheum Dis Clin North Am 29: 239-254
20. Novobrantseva TI, Majeau GR, Amatucci A et al. (2005) Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115: 3072-3082
21. Scheja A, Wildt M, Wollheim FA et al. (2000) Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology 39: 1110-1113
22. Shi-Wen X, Pennington D, Holmes A et al. (2000) Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 25: 213-224
23. Van den Brule S, Misson P, Buhling F et al. (2005) Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-beta. Respir Res 6: 84
24. Van der Slot AJ, Zuurmond AM, Bardoel AF et al. (2003). Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278: 40967-40972
25. Worda M, Sgonc R, Dietrich H et al. (2003) In vivo analysis of the apoptosis inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorioallantoic assay. Arthritis Rheum 48: 2605-2614
26. Yamamoto T, Eckes B, Krieg T (2001) High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 31: 2936-2941